ZA201505768B - Respirable agglomerates of porous carrier particles and micronized drug - Google Patents
Respirable agglomerates of porous carrier particles and micronized drugInfo
- Publication number
- ZA201505768B ZA201505768B ZA2015/05768A ZA201505768A ZA201505768B ZA 201505768 B ZA201505768 B ZA 201505768B ZA 2015/05768 A ZA2015/05768 A ZA 2015/05768A ZA 201505768 A ZA201505768 A ZA 201505768A ZA 201505768 B ZA201505768 B ZA 201505768B
- Authority
- ZA
- South Africa
- Prior art keywords
- carrier particles
- porous carrier
- micronized drug
- respirable agglomerates
- respirable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 | |
| PCT/IB2014/059739 WO2014141135A1 (en) | 2013-03-14 | 2014-03-13 | Respirable agglomerates of porous carrier particles and micronized drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201505768B true ZA201505768B (en) | 2017-03-29 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/05768A ZA201505768B (en) | 2013-03-14 | 2015-08-11 | Respirable agglomerates of porous carrier particles and micronized drug |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (https=) |
| EP (1) | EP2968570A1 (https=) |
| JP (1) | JP6374414B2 (https=) |
| KR (1) | KR20150129716A (https=) |
| CN (1) | CN105188757B (https=) |
| AU (2) | AU2014229265A1 (https=) |
| BR (1) | BR112015021814A2 (https=) |
| CA (1) | CA2905615A1 (https=) |
| CL (1) | CL2015002632A1 (https=) |
| EA (1) | EA201591729A1 (https=) |
| GT (1) | GT201500295A (https=) |
| HK (1) | HK1212616A1 (https=) |
| IL (1) | IL240963A (https=) |
| MA (1) | MA38397A1 (https=) |
| MX (1) | MX2015012814A (https=) |
| PE (1) | PE20151655A1 (https=) |
| PH (1) | PH12015501882A1 (https=) |
| SA (1) | SA515361055B1 (https=) |
| SG (1) | SG11201506397QA (https=) |
| TN (1) | TN2015000395A1 (https=) |
| WO (1) | WO2014141135A1 (https=) |
| ZA (1) | ZA201505768B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
| WO2014118532A1 (en) * | 2013-01-31 | 2014-08-07 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| KR20160137543A (ko) * | 2014-03-27 | 2016-11-30 | 노파르티스 아게 | 활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액 |
| RU2744460C2 (ru) | 2014-04-15 | 2021-03-09 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| WO2020247376A1 (en) * | 2019-06-03 | 2020-12-10 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| MX2022001884A (es) * | 2019-08-15 | 2022-03-11 | Abbott Lab | Proceso de fabricacion de polvo nutricional usando micronizacion y composicion en polvo. |
| KR20220167315A (ko) * | 2020-04-13 | 2022-12-20 | 유니버지퇴트슈피탈 바젤 | Lsd 용량 확인 |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| TW202237102A (zh) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 用於肺部遞送的藥物組合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| CN117355302A (zh) | 2021-04-30 | 2024-01-05 | 思维医学股份有限公司 | Lsd盐晶体形式 |
| JP2024529727A (ja) | 2021-08-19 | 2024-08-08 | マインド メディシン， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤 |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| CN116785246A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 一种药物微球及含其的气雾剂 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| WO2025256638A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海济昀生物科技有限公司 | 一种混悬型三联吸入气雾剂组合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| CZ282291B6 (cs) | 1991-06-26 | 1997-06-11 | Schering Corporation | Dávkovač prášku inhalačního zařízení pro prášková léčiva |
| WO1994014492A2 (en) | 1992-12-18 | 1994-07-07 | Schering Corporation | Inhaler for powdered medications |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| CZ289029B6 (cs) | 1994-09-21 | 2001-10-17 | Inhale Therapeutic Systems | Způsob aerosolizace práąku, zejména práąkového léku a zařízení k provádění tohoto způsobu |
| JP2000503565A (ja) | 1996-01-03 | 2000-03-28 | グラクソ、グループ、リミテッド | 吸入装置 |
| PT883415E (pt) | 1996-02-21 | 2002-10-31 | Schering Corp | Inalador para medicacao em po |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| DK0937041T3 (da) | 1996-11-11 | 2003-08-11 | Christian R Noe | Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| AU756852B2 (en) | 1998-11-13 | 2003-01-23 | Jagotec Ag | Dry powder for inhalation |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| EP1181069B1 (en) | 1999-05-28 | 2006-06-28 | Nektar Therapeutics | Apparatus and method for aerosolising a powder pharmaceutical composition |
| US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| ES2525087T5 (es) | 2000-05-10 | 2018-06-28 | Novartis Ag | Polvos basados en fosfolípidos para administración de fármacos |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| AU2003287132B2 (en) | 2002-12-13 | 2009-03-12 | Adagit | Pharmaceutical porous particles |
| US7559325B2 (en) | 2003-04-09 | 2009-07-14 | Novartis Pharma Ag | Aerosolization apparatus with air inlet shield |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| JP4708369B2 (ja) | 2004-02-24 | 2011-06-22 | マイクロドース セラピューテクス，インコーポレイテッド | 合成ジェットに基づく薬剤投与装置 |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| MY150468A (en) | 2006-06-30 | 2014-01-30 | Novartis Ag | Quinolinone derivatives and their pharmaceutical compositions |
| RU2463085C2 (ru) | 2006-10-25 | 2012-10-10 | Новартис Аг | Аппарат для распыления порошка, способ его изготовления и применения и его компоненты |
| WO2009140587A1 (en) | 2008-05-15 | 2009-11-19 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
| WO2010115937A1 (en) | 2009-04-09 | 2010-10-14 | Novartis Ag | Process for preparing pyrrolidinium salts |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| BR112012024059B1 (pt) | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Ceased
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en not_active Ceased
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150129716A (ko) | 2015-11-20 |
| MA38397A1 (fr) | 2018-01-31 |
| IL240963A (en) | 2017-05-29 |
| IL240963A0 (en) | 2015-11-30 |
| PE20151655A1 (es) | 2015-11-26 |
| AU2017203258A1 (en) | 2017-06-08 |
| CL2015002632A1 (es) | 2016-03-28 |
| GT201500295A (es) | 2017-09-28 |
| US9744178B2 (en) | 2017-08-29 |
| EA201591729A1 (ru) | 2016-05-31 |
| SG11201506397QA (en) | 2015-09-29 |
| JP6374414B2 (ja) | 2018-08-15 |
| SA515361055B1 (ar) | 2016-11-13 |
| MX2015012814A (es) | 2016-02-03 |
| BR112015021814A2 (pt) | 2017-07-18 |
| EP2968570A1 (en) | 2016-01-20 |
| AU2017203258B2 (en) | 2019-06-20 |
| AU2014229265A1 (en) | 2015-09-03 |
| TN2015000395A1 (en) | 2017-01-03 |
| US9452139B2 (en) | 2016-09-27 |
| CA2905615A1 (en) | 2014-09-18 |
| CN105188757A (zh) | 2015-12-23 |
| WO2014141135A1 (en) | 2014-09-18 |
| PH12015501882A1 (en) | 2015-12-07 |
| JP2016512494A (ja) | 2016-04-28 |
| US20160354388A1 (en) | 2016-12-08 |
| US20140302147A1 (en) | 2014-10-09 |
| HK1212616A1 (zh) | 2016-06-17 |
| CN105188757B (zh) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240963A (en) | Breathing agglomerates of airborne carrier particles and minimized drugs | |
| IL236666A0 (en) | Systems and methods for delivering a drug as a dry powder | |
| IL240291A0 (en) | History of pyridazinone and pharmaceutical preparations containing them | |
| EP3052551A4 (en) | Benefit agent containing delivery particle | |
| SG11201600707QA (en) | Substituted aminopyrimidine compounds and methods of use | |
| EP3063982A4 (en) | User equipment and methods of bearer operation for carrier aggregation | |
| SG11201510179PA (en) | Amino-triazine derivatives and pharmaceutical composition containing said derivatives | |
| SG11201505411RA (en) | Microdevices for separation of non-spherical particles and applications thereof | |
| EP3053937A4 (en) | Modified polytetrafluoroethylene fine powder and uniaxially oriented porous body | |
| HUE055773T2 (hu) | Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében | |
| PT3613421T (pt) | Ácido acetilsalicílico para reduzir o risco de um evento tromboembólico | |
| EP2964261A4 (en) | STABILIZATION OF MOISTURE-SENSITIVE DRUGS | |
| IL244496A0 (en) | Synthesis and particle engineering of co-crystals | |
| PT2994150T (pt) | Probióticos e métodos de utilização | |
| EP3006106A4 (en) | Catalyst particles, loaded catalyst particles, and use of same | |
| IL240505A0 (en) | Accumulations of lanthanides and methods for their use | |
| GB201806558D0 (en) | Superfically porous particles with precisely controlled particle density and methods of preparation and use thereof | |
| IL240292A0 (en) | History of quinazoline and pharmaceutical preparations containing them | |
| IL276838B (en) | Oral formulation and suspension of an oncology drug | |
| ZA201507706B (en) | Inhalable pharmaceutical compositions and the inhaler devices containing them | |
| IL241070A0 (en) | Powder particles with additional coating | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| GB201307659D0 (en) | Preparation of drug particles by micronisation | |
| GB201415815D0 (en) | Size reduction device and method for the size reduction of solid particles | |
| AU2013205497B2 (en) | Dry powder inhaler and methods of use |